Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arrowhead Pharmaceuticals

10.68
-1.3800-11.44%
Post-market: 10.680.00000.00%18:43 EDT
Volume:2.57M
Turnover:27.99M
Market Cap:1.47B
PE:-2.07
High:11.96
Open:11.74
Low:10.66
Close:12.06
Loading ...

Company Profile

Company Name:
Arrowhead Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2003
Employees:
609
Office Location:
177 East Colorado Boulevard,Suite 700,Pasadena,California,United States
Zip Code:
91105
Fax:
626 304 3401
Introduction:
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Directors

Name
Position
Christopher Anzalone
Chief Executive Officer, President & Director
Adeoye Olukotun
Independent Director
Douglass Given
Board Chair
Marianne De Backe
Independent Director
Mauro Ferrari
Independent Director
Michael S. Perry
Independent Lead Director
Victoria Vakiener
Independent Director
William Waddill
Independent Director

Shareholders

Name
Position
Christopher Anzalone
Chief Executive Officer, President & Director
Patrick O'Brien
Chief Operating Officer and General Counsel
Kenneth A. Myszkowski
Chief Financial Officer
James Hamilton
Chief of Discovery and Translational Medicine
Javier San Martin
Chief Medical Officer
Tracie Oliver
Chief Commercial Officer